Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

How pharma can make drug information accessible

Posted on June 1st, 2022 by

Medical Information

Pharmaceutical drugs can work wonders for patients, whether it’s treating rare diseases or easing everyday maladies. But drugs can also be complex. What works for one patient may not for another, and side effects could be possible. Also, the longer that a drug is on the market, the more its manufacturer might learn and document about its effects. All of this information is important, and in order to prescribe drugs wisely, doctors need access to it.

(more…)

Reaxys User Day 2022: Researcher secrets in the spotlight

Posted on May 26th, 2022 by

Chemistry

In April, Elsevier hosted the first Reaxys User Day to learn from expert users and share best practices. Attendees were also updated on how the expert-curated chemistry database has dramatically upped its ability to streamline R&D. We spoke with senior director Ivan Krstic about how Reaxys is turning data into actionable insights to better understand the competitive landscape, design novel compounds, and generally accelerate synthetic chemistry. “Today is about sharing the amazing strides we’ve made,” says Ivan.

(more…)

Taking on the Net Zero challenge at the government level

Posted on May 24th, 2022 by

Pharma R&D

Life sciences companies are increasingly committing themselves to Net Zero goals, laying out plans for reaching zero emissions by 2050 or earlier. This is a vitally important step for industry. But national, state and city governments also have a critical role in reducing emissions created by various sectors under their jurisdiction.

(more…)

Pharma’s path to Net Zero

Posted on May 3rd, 2022 by

Pharma R&D

Pharma is seldom top of mind when thinking about the most polluting industries, but pharmaceutical industry operations are in fact responsible for a significant portion of the world’s greenhouse gas emissions – even rivaling industries that are far more associated with contributing to the problem. 

(more…)

Elsevier and LG: Turning data into action

Posted on April 28th, 2022 by

AI & Data

There are life-changing insights waiting to be found in chemistry data. The critical information waiting to be unlocked can lead to incredible technology advances and medical breakthroughs. But there is so much data out there, and it is multiplying rapidly. At Elsevier, we are excited about a new partnership with world-renowned innovator LG that we are confident will enable researchers to discover and surface more relevant chemistry facts and relationships from scientific literature than ever before.

(more…)

Pharma can now track the most relevant patent info – fast and at scale

Posted on April 26th, 2022 by

AI & Data

Since its initial release in January 2021, AI-fueled Patent Expansion in Reaxys has won the respect of pharmaceutical companies trying to stay ahead of their competitors by keeping track of the latest patents around drug discovery and new therapeutics. With a recent expansion that allows Reaxys to also loop in information from images found in patents, it’s a good time to look back – and forward – at this continual work-in-progress. We spoke to Umesh Nandal, Elsevier’s Director of Data Science, about the logic behind the tech: “It’s not just about the speed of access to all this annotated data, but the quality.”

(more…)

  1. 1
  2. 2
  3. 3
  4. 4
  5. 90

About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.